Profusa, Inc. / NorthView Acquisition Corp. — Q1 2023 Form 10-Q
Entity note: The filing is for NorthView Acquisition Corp., a blank-check company that had signed a merger agreement with Profusa, Inc. It is not a quarterly operating report for Profusa. The reporting period ended March 31, 2023.
Business context and reporting period
NorthView was formed to complete a business combination and reported no operations or operating revenue through March 31, 2023. Its stated focus was healthcare innovation. In November 2022, it agreed to merge with Profusa, with Profusa surviving as a wholly owned subsidiary and NorthView changing its name to Profusa, Inc. The transaction remained subject to customary conditions, including stockholder approvals, governmental approvals, and a minimum available cash condition of $15 million; completion was not assured.
Key financial metrics
| Metric | Q1 2023 / March 31, 2023 | Prior comparable period / December 31, 2022 |
|---|---|---|
| Operating revenue | None | None |
| Net income | $440,895 | $3,709,017 in Q1 2022 |
| Formation and operating costs | $443,717 | $241,596 in Q1 2022 |
| Interest income from Trust Account | $1,845,005 | $72,684 in Q1 2022 |
| Change in fair value of warrant liabilities | $574,137 loss | $3,877,929 gain in Q1 2022 |
| Cash and cash equivalents | $55,610 | $193,486 |
| Cash and marketable securities in Trust Account | $10,392,055 | $194,224,782 |
| Working capital | $1,947,395 deficit | Not clearly stated for December 31, 2022 |
| Total liabilities | $4,087,411 | $1,830,478 |
| Long-term debt | None reported | None reported |
| Net cash used in operating activities | $966,607 | $230,352 in Q1 2022 |
Net income in both periods was driven largely by non-operating items, especially changes in warrant fair value and Trust Account interest; it does not represent operating profitability. No operating margin is meaningful because the company had no revenue.
Material changes versus the prior comparable period
- Net income fell to $440,895 from $3.71 million, primarily because the prior-year period included a $3.88 million warrant fair-value gain, while Q1 2023 recorded a $574,137 loss on warrant remeasurement.
- Trust Account interest rose to $1.85 million from $72,684, while operating costs increased to $443,717 from $241,596.
- On March 22, 2023, shareholders redeemed 18,000,868 shares for $184.85 million. Trust assets declined to $10.39 million from $194.22 million at year-end 2022; redeemable shares fell to 974,132 from 18,975,000.
- The company recorded a $1,848,455 excise-tax liability/charge associated with the redemptions, calculated at 1% of the redemption amount.
Outlook, risks, contingencies and unusual items
- NorthView had until May 22, 2023, with extensions potentially available through December 22, 2023, to complete a business combination. Management stated that failure to complete a transaction could lead to mandatory liquidation and raised substantial doubt about the company’s ability to continue as a going concern for the next 12 months.
- The Profusa merger agreement specified a $155 million pre-transaction equity value and up to 3.875 million additional shares tied to future stock-price and revenue milestones. The stated revenue thresholds were $5.1 million for fiscal 2023 and $73.1 million for fiscal 2024; these are transaction earnout conditions, not company guidance.
- The merger’s $15 million minimum available cash condition is significant in light of the $10.39 million Trust Account balance at quarter-end. The filing does not establish that this condition was met or explain fully how any shortfall would be funded.
- On April 27, 2023, after quarter-end, NorthView signed a non-interest-bearing Sponsor working-capital note for up to $1.2 million, due at a business combination or liquidation and convertible at the Sponsor’s option into warrants at $1 each. It had drawn $168,589 by that date.
- Management identified COVID-19 and the Russia-Ukraine war as potential risks but said the specific impact was not readily determinable. The filing reported no legal proceedings, no long-term debt, and no off-balance-sheet arrangements.
- Disclosure controls and procedures were assessed as effective at March 31, 2023; no material changes in internal control over financial reporting were reported.
Important facts for investors to verify
- Whether the Profusa business combination closed, received required approvals, and satisfied the $15 million minimum cash condition.
- Whether extensions were obtained and whether NorthView faced liquidation; the filing’s stated deadlines and extension options are time-sensitive.
- How the $1.85 million excise-tax liability and any later redemptions or share issuances affected cash available for the transaction.
- Use, repayment, and any conversion of the Sponsor note, as well as other financing raised to meet transaction needs.
- That the reported earnings are NorthView SPAC results, not Profusa operating results; this filing provides no clear Profusa revenue, profit, cash flow, or operating margin values.